MCID: MSC003
MIFTS: 50

Muscular Atrophy malady

Categories: Muscle diseases, Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Muscular Atrophy

Aliases & Descriptions for Muscular Atrophy:

Name: Muscular Atrophy 12 42 14 69
Muscle Wasting 12 14
Skeletal Muscle Atrophy 69
Wasting - Muscle 12
Amyotrophia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:767
MeSH 42 D009133
NCIt 47 C94834
UMLS 69 C0026846

Summaries for Muscular Atrophy

MalaCards based summary : Muscular Atrophy, also known as muscle wasting, is related to spinal muscular atrophy-4 and spinal muscular atrophy-3, and has symptoms including muscular fasciculation, muscle cramp and spasm. An important gene associated with Muscular Atrophy is SMN1 (Survival Of Motor Neuron 1, Telomeric). The drugs Pioglitazone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include skeletal muscle, testes and spinal cord, and related phenotype is muscle.

Related Diseases for Muscular Atrophy

Diseases in the Muscular Atrophy family:

Progressive Muscular Atrophy

Diseases related to Muscular Atrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 227)
id Related Disease Score Top Affiliating Genes
1 spinal muscular atrophy-4 33.3 NAIP SMN1 SMN2
2 spinal muscular atrophy-3 32.9 IGHMBP2 NAIP SMN1 SMN2 ZPR1
3 spinal muscular atrophy 12.6
4 spinal and bulbar muscular atrophy of kennedy 12.5
5 progressive muscular atrophy 12.4
6 spinal muscular atrophy, lower extremity-predominant, 2, ad 12.4
7 spinal muscular atrophy with progressive myoclonic epilepsy 12.3
8 scapuloperoneal spinal muscular atrophy 12.3
9 spinal muscular atrophy, x-linked 2, infantile 12.3
10 spinal muscular atrophy, lower extremity-predominant 1, ad 12.3
11 spinal muscular atrophy, late-onset, finkel type 12.3
12 spinal muscular atrophy, distal, autosomal recessive, 2 12.3
13 spinal muscular atrophy, distal, congenital nonprogressive 12.3
14 spinal muscular atrophy, distal, autosomal recessive, 4 12.3
15 spinal muscular atrophy, distal, x-linked 3 12.3
16 spinal muscular atrophy, distal, autosomal recessive, 5 12.2
17 spinal muscular atrophy, jokela type 12.2
18 survival motor neuron spinal muscular atrophy 12.2
19 spinal muscular atrophy, distal, autosomal recessive, 3 12.2
20 proximal spinal muscular atrophy 12.1
21 juvenile spinal muscular atrophy 12.1
22 spinal muscular atrophy type 1 with congenital bone fractures 12.1
23 neuronopathy, distal hereditary motor, type vi 12.0
24 adult spinal muscular atrophy 12.0
25 spinal muscular atrophy-2 12.0
26 pelvic muscle wasting 12.0
27 spinal muscular atrophy with respiratory distress type 2 12.0
28 spinal muscular atrophy-1 12.0
29 autosomal dominant childhood-onset proximal spinal muscular atrophy 12.0
30 spastic paraplegia and distal muscle wasting caused by neuropathy target esterase gene mutation 11.9
31 mental retardation, x-linked, with short stature, small testes, muscle wasting, and tremor 11.9
32 spinal muscular atrophy-dandy-walker malformation-cataracts syndrome 11.9
33 troyer syndrome 11.9
34 muscular atrophy, ataxia, retinitis pigmentosa, and diabetes mellitus 11.9
35 spinal muscular atrophy, lower extremity, autosomal dominant 11.9
36 spinal muscular atrophy ryukyuan type 11.8
37 adult progressive spinal muscular atrophy aran duchenne type 11.8
38 distal spinal muscular atrophy 4 11.8
39 arthrogryposis spinal muscular atrophy 11.8
40 congenital benign spinal muscular atrophy dominant 11.8
41 amyotrophy, monomelic 11.7
42 charcot-marie-tooth disease 11.7
43 neuronopathy, distal hereditary motor, type i 11.7
44 primrose syndrome 11.6
45 neuropathy, distal hereditary motor, type va 11.5
46 neuronopathy, distal hereditary motor, type vb 11.5
47 autoinflammation, lipodystrophy, and dermatosis syndrome 11.5
48 mental retardation, x-linked, syndromic 15 11.4
49 motor neuron disease 11.4
50 pontocerebellar hypoplasia type 1a 11.4

Graphical network of the top 20 diseases related to Muscular Atrophy:



Diseases related to Muscular Atrophy

Symptoms & Phenotypes for Muscular Atrophy

UMLS symptoms related to Muscular Atrophy:


muscular fasciculation, muscle cramp, spasm, muscle weakness, myokymia, neuromuscular manifestations

MGI Mouse Phenotypes related to Muscular Atrophy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.23 AR ATP7A DYNC1H1 IGHMBP2 PLEKHG5 SMN2

Drugs & Therapeutics for Muscular Atrophy

Drugs for Muscular Atrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 445)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
3
Ramipril Approved Phase 4 87333-19-5 5362129
4
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
5
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
6
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
7
Fosinopril Approved Phase 4 98048-97-6 55891
8
Alendronate Approved Phase 4 121268-17-5, 66376-36-1 2088
9
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
10
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
11
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 171596-29-5 110635
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Allopurinol Approved Phase 4 315-30-0 2094
14
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
15
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 1 67-97-0 6221 10883523 5280795
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 50-14-6 5280793
17 insulin Phase 4,Phase 2,Phase 3,Phase 1
18 Testosterone undecanoate Phase 4,Phase 3,Phase 2,Phase 1
19
protease inhibitors Phase 4,Phase 3,Phase 2
20 Cholinergic Agents Phase 4,Phase 2,Phase 1
21 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Adrenergic Antagonists Phase 4,Phase 2,Phase 3
23 Neuromuscular Agents Phase 4,Phase 1,Phase 2
24 Adrenergic alpha-1 Receptor Antagonists Phase 4
25 Adrenergic alpha-Antagonists Phase 4
26 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
27 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
28 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
29
Testosterone enanthate Phase 4,Phase 3,Phase 2,Phase 1 315-37-7 9416
30 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2
31 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Androgens Phase 4,Phase 3,Phase 2,Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
39 Angiotensin-Converting Enzyme Inhibitors Phase 4,Phase 3,Phase 2
40 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
42 abobotulinumtoxinA Phase 4,Phase 2,Phase 1
43 incobotulinumtoxinA Phase 4,Phase 2,Phase 1
44 onabotulinumtoxinA Phase 4,Phase 2,Phase 1
45 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Insulin, Globin Zinc Phase 4,Phase 2,Phase 3,Phase 1
47 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
50 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 977)
id Name Status NCT ID Phase
1 Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Unknown status NCT01253928 Phase 4
2 Botulinum A Toxin in Patients With Parkinson's Disease Unknown status NCT00822913 Phase 4
3 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4
4 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4
5 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4
6 Physiologic Effects of PRMS & Testosterone in the Debilitated Elderly Completed NCT00018356 Phase 4
7 Myobloc Atrophy Study Completed NCT02052024 Phase 4
8 Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial Completed NCT01372176 Phase 4
9 TENS in Optimizer(R) Patients Completed NCT02692690 Phase 4
10 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01014338 Phase 4
11 Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome Completed NCT02140632 Phase 4
12 Sleep and Training Aspects in Dialysis Fatigue - Exercise Intervention Completed NCT01721551 Phase 4
13 Study of The Effects of Testosterone in Frail Elderly Men Completed NCT00190060 Phase 4
14 Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men Completed NCT00957801 Phase 4
15 Upper Facial Remodeling With Perlane-L and Dysport Completed NCT01354743 Phase 4
16 Tadalafil in Becker Muscular Dystrophy Completed NCT01070511 Phase 4
17 PDE5 Inhibition to Alleviate Functional Muscle Ischemia in Becker Muscular Dystrophy Completed NCT02207283 Phase 4
18 Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy Completed NCT01882400 Phase 4
19 Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty Recruiting NCT02926235 Phase 4
20 Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS Recruiting NCT02276066 Phase 4
21 Body Composition Measurements in Chronic Heart Failure Recruiting NCT02686866 Phase 4
22 Stacking Exercises Aid the Decline in FVC and Sick Time Active, not recruiting NCT01999075 Phase 4
23 Allopurinol in Functional Impairment (ALFIE) Trial: 'Improving Muscle Strength' Enrolling by invitation NCT01550107 Phase 4
24 LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD Not yet recruiting NCT02568020 Phase 4
25 Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease Not yet recruiting NCT02704624 Phase 4
26 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Not yet recruiting NCT02462018 Phase 4
27 TOM: Testosterone in Older Men With Sarcopenia Terminated NCT00240981 Phase 4
28 The Effects of Long Term Cyclic Testosterone Administration on Muscle Function and Bone in Older Men Withdrawn NCT01417364 Phase 4
29 Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy Unknown status NCT01344135 Phase 3
30 Study to Assess the Efficacy and Safety of Ibuprofen 50 mg/g Gel Compared to Profenid 25mg/g Gel Unknown status NCT01373697 Phase 3
31 Testosterone Administration and ACL Reconstruction in Men Unknown status NCT01595581 Phase 3
32 Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China Unknown status NCT01873547 Phase 3
33 Laparoscopic Inguinal Hernia Repair in Infancy and Childhood Unknown status NCT02239185 Phase 3
34 Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy Unknown status NCT02147639 Phase 2, Phase 3
35 RAMYD Study - Evaluation of Arrhythmic Risk in Myotonic Dystrophy Unknown status NCT00127582 Phase 3
36 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) Completed NCT02292537 Phase 3
37 A Trial of Hydroxyurea in Spinal Muscular Atrophy Completed NCT00485511 Phase 2, Phase 3
38 A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Completed NCT02193074 Phase 3
39 Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients Completed NCT01645787 Phase 2, Phase 3
40 Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum Completed NCT01355497 Phase 3
41 Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) Completed NCT01355484 Phase 3
42 Study to Evaluate the Efficacy of Riluzole in Children and Young Adults With Spinal Muscular Atrophy (SMA) Completed NCT00774423 Phase 2, Phase 3
43 Metabolism and Oxygen Consumption During Functional Electrical Stimulation Cycling in COPD Completed NCT02594722 Phase 3
44 Strength Training in Walking Tolerance in Intermittent Claudication Patients Completed NCT00879697 Phase 3
45 A Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3
46 Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support Completed NCT00268944 Phase 3
47 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3
48 Effect of Ursolic Acid of Loquat Extract on Function of Muscle Completed NCT02401113 Phase 2, Phase 3
49 Resistance Exercise, Muscle Mass, Strength and Body Composition Completed NCT01766791 Phase 3
50 The Combined Effects of Resistance Training and Flax Oil Supplementation Upon Inflammation in Older Adults Completed NCT00465153 Phase 3

Search NIH Clinical Center for Muscular Atrophy

Cochrane evidence based reviews: muscular atrophy

Genetic Tests for Muscular Atrophy

Anatomical Context for Muscular Atrophy

MalaCards organs/tissues related to Muscular Atrophy:

39
Skeletal Muscle, Testes, Spinal Cord, Bone, Heart, Brain, Prostate

Publications for Muscular Atrophy

Articles related to Muscular Atrophy:

(show top 50) (show all 1412)
id Title Authors Year
1
A qualitative study of perceptions of meaningful change in spinal muscular atrophy. ( 28376816 )
2017
2
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. ( 28460889 )
2017
3
Adult-onset spinal muscular atrophy: An update. ( 28456383 )
2017
4
Combination of valproic acid and morpholino splice-switching oligonucleotide produces improved outcomes in spinal muscular atrophy patient-derived fibroblasts. ( 28389270 )
2017
5
Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis. ( 28132687 )
2017
6
Raise the Roof: Boosting the Efficacy of a Spinal Muscular Atrophy Therapy. ( 28056344 )
2017
7
A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. ( 28460014 )
2017
8
Transcript levels of plastin 3 and neuritin 1 modifier genes in spinal muscular atrophy siblings. ( 27279027 )
2017
9
Oligodendrocyte development and CNS myelination are unaffected in a mouse model of severe spinal muscular atrophy. ( 28069797 )
2017
10
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular Atrophy. ( 28017471 )
2017
11
Evaluation and comparison of three assays for molecular detection of spinal muscular atrophy. ( 27754957 )
2017
12
Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. ( 28426667 )
2017
13
Longitudinal characterization of biomarkers for spinal muscular atrophy. ( 28491897 )
2017
14
Decreased microRNA levels lead to deleterious increases in neuronal M2 muscarinic receptors in Spinal Muscular Atrophy models. ( 28463115 )
2017
15
Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy. ( 28251733 )
2017
16
Newborn screening for spinal muscular atrophy: The views of affected families and adults. ( 28374951 )
2017
17
SMN deficiency negatively impacts red pulp macrophages and spleen development in mouse models of Spinal Muscular Atrophy. ( 28062667 )
2017
18
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. ( 27939059 )
2017
19
Effect of electroacupuncture on the expression of agrin and acetylcholine receptor subtypes in rats with tibialis anterior muscular atrophy induced by sciatic nerve injection injury. ( 28069562 )
2017
20
Discovery of a Small Molecule Probe That Post-Translationally Stabilizes the Survival Motor Neuron Protein for the Treatment of Spinal Muscular Atrophy. ( 28481536 )
2017
21
Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in model mice. ( 28379354 )
2017
22
Reduced sensory synaptic excitation impairs motor neuron function via Kv2.1 in spinal muscular atrophy. ( 28504671 )
2017
23
Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA). ( 28257199 )
2017
24
Cardiac pathology in spinal muscular atrophy: a systematic review. ( 28399889 )
2017
25
Correction: Hyperleptinemia in children with autosomal recessive spinal muscular atrophy type I-III. ( 28384258 )
2017
26
Genetic screening of spinal muscular atrophy using a real-time modified COP-PCR technique with dried blood-spot DNA. ( 28522225 )
2017
27
Another milestone in childhood spinal muscular atrophy. ( 28460890 )
2017
28
Serum cytokine and chemokine profiles in patients with juvenile muscular atrophy of distal upper extremity (Hirayama disease). ( 27956076 )
2017
29
An Evaluation of a Continuing Education Program for Family Caregivers of Ventilator-Dependent Children with Spinal Muscular Atrophy (SMA). ( 28468263 )
2017
30
Linking Amyotrophic Lateral Sclerosis and Spinal Muscular Atrophy through RNA-transcriptome homeostasis: a genomics perspective. ( 28054357 )
2017
31
ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy. ( 28400976 )
2017
32
Discovery of a Novel Class of Survival Motor Neuron 2 Splicing Modifiers for the Treatment of Spinal Muscular Atrophy. ( 28441483 )
2017
33
Dawn of a new therapeutic era for spinal muscular atrophy. ( 27939062 )
2017
34
How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy. ( 28485722 )
2017
35
Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. ( 28087734 )
2017
36
Sensory Neuronopathy in Spinal Muscular Atrophy: A Case Presentation. ( 27552391 )
2016
37
Introduction to the Special Issue on Spinal and Bulbar Muscular Atrophy. ( 26875173 )
2016
38
Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy. ( 27005422 )
2016
39
Clinical applications of MARSALA for preimplantation genetic diagnosis of spinal muscular atrophy. ( 27599922 )
2016
40
Spinal Muscular Atrophy, types I and II: What are the differences inA body composition and resting energy expenditure? ( 27890489 )
2016
41
Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. ( 27652289 )
2016
42
What Matters Most: A Perspective From Adult Spinal Muscular Atrophy Patients. ( 27854231 )
2016
43
Spinal Muscular Atrophy: More than a Disease of Motor Neurons? ( 27894243 )
2016
44
Six-Minute Walk Test is Reliable and Valid in Spinal Muscular Atrophy. ( 27015431 )
2016
45
A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls. ( 27893852 )
2016
46
Spinal muscular atrophy associated with progressive myoclonic epilepsy. ( 27647482 )
2016
47
Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. ( 27014701 )
2016
48
TRPV4 related scapuloperoneal spinal muscular atrophy: Report of an Italian family and review of the literature. ( 26948711 )
2016
49
Management of scoliosis in patients with Duchenne muscular dystrophy and spinal muscular atrophy: A literature review. ( 26966797 )
2016
50
Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy. ( 27042141 )
2016

Variations for Muscular Atrophy

Expression for Muscular Atrophy

Search GEO for disease gene expression data for Muscular Atrophy.

Pathways for Muscular Atrophy

GO Terms for Muscular Atrophy

Cellular components related to Muscular Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.88 IGHMBP2 PLEKHG5 SMN1 SMN2 TRPV4 ZPR1
2 neuron projection GO:0043005 9.73 ATP7A NAIP SMN1 SMN2
3 growth cone GO:0030426 9.63 IGHMBP2 TRPV4 ZPR1
4 Cajal body GO:0015030 9.56 SMN1 SMN2 SMNDC1 ZPR1
5 perikaryon GO:0043204 9.55 ATP7A NAIP SMN1 SMN2 ZPR1
6 SMN-Sm protein complex GO:0034719 9.5 DDX20 SMN1 SMN2
7 cytoplasmic ribonucleoprotein granule GO:0036464 9.48 SMN1 SMN2
8 Gemini of coiled bodies GO:0097504 9.26 DDX20 SMN1 SMN2 ZPR1
9 SMN complex GO:0032797 9.02 DDX20 IGHMBP2 SMN1 SMN2 ZPR1
10 cytoplasm GO:0005737 10.24 AR ATP7A BICD2 DDX20 DYNC1H1 IGHMBP2

Biological processes related to Muscular Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mRNA processing GO:0006397 9.65 DDX20 SMN1 SMN2 SMNDC1 ZPR1
2 RNA splicing GO:0008380 9.55 DDX20 SMN1 SMN2 SMNDC1 ZPR1
3 DNA-templated transcription, termination GO:0006353 9.32 SMN1 SMN2
4 spliceosomal snRNP assembly GO:0000387 9.13 DDX20 SMN1 SMN2
5 nuclear import GO:0051170 8.8 DDX20 SMN1 SMN2

Molecular functions related to Muscular Atrophy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.5 ATP7A DDX20 DYNC1H1 IGHMBP2 NAIP TRPV4
2 dynein light intermediate chain binding GO:0051959 8.62 BICD2 DYNC1H1
3 protein binding GO:0005515 10.06 AR ATP7A BICD2 DDX20 DYNC1H1 GTF2H2

Sources for Muscular Atrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....